Needham raised the firm’s price target on Revolution Medicines to $46 from $36 and keeps a Buy rating on the shares. The company this week reported positive preclinical data in G13X and Q61X supported by clinical activity in three patients with non-G12C mutations in pancreatic ductal adenocarcinoma, colorectal cancer and melanoma, the analyst tells investors in a research note. The firm says the preclinical data support that the combination of RMC-6236 and RMC-6291 can generate meaningful improvement in durability in addition to higher response rates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines upgraded to Strong Buy from Outperform at Raymond James
- Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
- Revolution Medicines announces publications on discovery of RMC-7977
- Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
- Revolution Medicines to Participate in Upcoming Investor Conferences
